ArticleBioMed research international2014
Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.British journal of cancer · 2017Pooled it
- Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.ACS pharmacology & translational science · 2024Review
- Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43.Viruses · 2023Article
- Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma.Archives of medical science : AMS · 2023Article
- Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.Frontiers in endocrinology · 2022Article
- Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion.Biomolecules · 2021Article
- Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review.Translational lung cancer research · 2021Review
- Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells.Cancers · 2021Article
- Circulating biomarkers in malignant pleural mesothelioma.Exploration of targeted anti-tumor therapy · 2020Review
- Soluble syndecans: biomarkers for diseases and therapeutic options.British journal of pharmacology · 2019Review
- Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1.BMC cell biology · 2017Article
- Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.BMC cancer · 2017Article
- Mechanisms of heparanase inhibitors in cancer therapy.Experimental hematology · 2016Review
- Article
- Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.Oncotarget · 2015Review
- CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.Cancer immunology, immunotherapy : CII · 2015Article
- Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.Disease markers · 2015Review
- Proteoglycans in Mechanobiology of Tissues and Organs: Normal Functions and Mechanopathology.Proteoglycan researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe distinction between malignant and benign pleural effusions is a diagnostic challenge today and measuring soluble biomarkers could add to the diagnostic accuracy. Syndecan-1 is a proteoglycan involved in various cellular functions and is cleaved from the cell surface in a regulated manner. The shed fragment, which can be recovered in effusion supernatant and in serum, retains its binding capacities, but often with different functions and signalling properties than the cell-bound form.
aimThis study aimed to investigate the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera from patients with pleural malignancies. STUDY
designUsing two cohorts of patients, we assessed the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera, using enzyme-linked immunosorbent assays.
resultsIn pleural effusions, syndecan-1 distinguished malignant and benign diseases, with an odds ratio of 8.59 (95% CI 3.67 to 20.09). Furthermore, syndecan-1 in pleural effusions predicted a survival difference for patients with pleural metastatic disease and malignant mesothelioma of 11.2 and 9.2 months, respectively. However, no such effects were seen when syndecan-1 was measured in serum.
conclusionSoluble syndecan-1 is a promising candidate biomarker for the cytopathological diagnosis and prognostication of malignant pleural effusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.